NRx Pharmaceuticals (NSDQ:NRXP) announced that it applied for FDA emergency use authorization based on a study of its Zyesami therapeutic. Radnor, Pa.-based NRx Pharmaceuticals, formerly NeuroRx, just last week completed a merger with SPAC Big Rock Partners Acquisition Corp. and went public, changing its name in the process. The company develops Zyesami, a synthetic form […]
NeuroRx
NeuroRx completes merger with SPAC, starts trading on Nasdaq
NeuroRx announced today that it commenced trading on the Nasdaq market following its merger with Big Rock Partners Acquisition Corp. The combined business entity will be known as NRx Pharmaceuticals and will trade on the Nasdaq market under the NRXP ticker, according to a news release. Radnor, Pa.-based NRx develops Zyesami, a synthetic form of […]
NeuroRX, TFF Pharmaceuticals enter feasibility agreement for Zyesami dry powder for COVID-19
NeuroRx and TFF Pharmaceuticals (NSDQ:TFFP) announced a feasibility agreement for the former’s Zyesami therapeutic. Zyesami (aviptadil, synthetic VIP) materials are set to be delivered to TFF to perform feasibility formulation work and testing in an effort to identify an optimal, long-term, stable formulation of Zyesami into a dry powder form for aerosol delivery directly to […]
